Tag: Bharat Biotech
Ocugen expands COVAXIN commercialization rights to include Canada
Ocugen to have exclusive co-development, manufacturing, and commercialization rights to COVAXIN in Canada, in addition to its existing US rights.....................
From vaccine to vaccination: It takes 120 days for a Covaxin...
The timeline for vaccine supplies to reach the depots of the State and Central Governments from Bharat Biotech’s facilities is around two days............................
Bharat Biotech to soon touch 1 billion COVAXIN doses per annum
Having already deployed multiple production lines at its Hyderabad and Bengaluru campuses, Bharat Biotech has recently added Chiron Behring to this line up of high containment BSL rated GMP facilities...................
COVAXIN demonstrates interim clinical efficacy of 78% in phase 3 trials
The second interim results showed India’s First COVID-19 Vaccine had demonstrated strong primary efficacy against severe COVID-19 disease.......................
Scale up the production capacity: PM Modi tells vaccine manufacturers
The prime minister, Narendra Modi interacted with vaccine manufacturers from across the country on April 20, 2021........................
Bharat Biotech to ramp up Covaxin production by 700 million doses...
The capacity expansion has been implemented across multiple facilities in Hyderabad and Bangalore, to reach ~ 700 million doses per year, one of the largest production capacities for Inactivated viral vaccines worldwide.................................
Govt targets 6-7 fold increase in COVAXIN production by August, 2021
The current production capacity of indigenously developed Covaxin vaccine is expected to be doubled by May-June 2021 and then increased nearly 6-7 fold by July - August 2021 under Mission COVID Suraksha......................
Govt fast tracks emergency approvals for foreign produced COVID-19 vaccines
A lot many vaccines are expected to be granted Emergency Use Authorization in other countries for expanding the basket of vaccines for domestic use and hasten the pace and coverage of vaccination....................
Bharat Biotech’s COVAXIN Phase 3 results show interim clinical efficacy of...
Data from 25,800 participants that received the COVAXIN vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well-tolerated. It demonstrated 81% interim efficacy in preventing COVID-19 after the second dose....................
Bharat Biotech confirms deal with Brazil to supply 20 million doses...
It has signed an agreement for the delivery of COVAXIN during the second and third quarter of the year 2021.....................